Therapeutic antibodies coming through the pipeline

Analytical Chemistry

Volumn 80, Issue 7, 2008, Pages 2305-2310

  Piggee, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; ETANERCEPT; FANOLESOMAB TC 99M; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MYOSIN ANTIBODY IN 111; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; SULESOMAB; SULESOMAB TC 99M; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUMA;

ANALYTIC METHOD; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; DISULFIDE BOND; DRUG CONFORMATION; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MONITORING; DRUG PURIFICATION; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; IMMUNOGENICITY; REVIEW;

ANIMALS; ANTIBODIES; HUMANS; PROTEIN ENGINEERING; TIME FACTORS;

EID: 41849115607     PISSN: 00032700     EISSN: None     Source Type: Journal    
DOI: 10.1021/ac086033v     Document Type: Review

References (16)

1. U.S. Patent and Trademark Office. Patent Full-Text and Full-Page Image Databases; www.uspto.gov/patft/index.html.
2. Reichert, J. M.; et al. Nat. Biotechnol. 2005, 23, 1073-1078.
3. Lawrence, S. Nat. Biotechnol. 2007, 25, 1342.
4. Filpula, D. Biomol. Eng. 2007, 24, 201-215.
5. Morrow, K. J., Jr. Genet. Eng Biotechnol. News 2006, 26, 54-58.
6. Dubois, M.; et al. Anal. Chem. 2008, 80, 1737-1745.
7. Yang, Z.; et al. Anal. Chem. 2007, 79, 9294-9301.
8. Wang, L.; Hale, G.; Ghosh, R. Anal. Chem. 2006, 78, 6863-6867.
9. Vitetta, E. S.; Ghetie, V. F. Science 2006, 313, 308-309.
10. Nissim, A.; Chernajovsky, Y. Historical Development of Monoclonal Antibody Therapeutics. In Therapeutic Antibodies; Nissim, A., Chernajovsky, Y., Eds.; Handbook of Experimental Pharmacology, Vol. 181; Springer-Verlag: Berlin, 2008; pp 3-18.
11. Binz, H. K.; Amstutz, P.; Plückthun, A. Nat. Biotechnol. 2005, 23, 1257-1268.
12. IBC Life Sciences. The Annual Forum of the Antibody Engineering Community Conveying the Insights Needed To Pioneer Future Developments in Antibody Engineering and Immunotherapeutics, San Diego, Dec 2-6, 2007; www.ibclifesciences.com/antibodyeng/6687.xml.
13. Brekke, O. H.; Sandlie, I. Nat. Rev. Drug Discov. 2002, 2, 52-62.
14. Teillaud, J.-L. Expert Opin. Biol. Ther. 2005, 5, S1-S13.
15. Complete List of Stems for Monoclonal Antibody Nomenclature; http://en.wikipedia.org/wiki/Nomenclature_of_monoclonal_antibodies.
16. World Health Organization Programme on International Nonproprietary Names (INN). Pre-Stems: Suffixes Used in the Selection of INNs; www.who.int/medicines/services/inn/5-Prestem_POSTMeeting_Nov07.pdf.